BioSpace News Archive

Nephron Pharmaceuticals Corporation, one of the fastest-growing pharmaceuticals companies in the country, today announced a new collaboration with Methapharm.

Julius Group, a leading innovative manufacturer that combines the latest technologies with heritage craftsmanship to produce gloves and fashion accessories, and Noble Biomaterials, the global leader in antimicrobial and conductivity solutions for soft-surface applications, today announced the launch of a strategic partnership to produce reusable antiviral/antibacterial gloves and masks for consumer use.

HYGIENICA, the San Diego-based maker of industry-leading disinfecting technology, has closed its Seed Round of financing.

Ancestry®, the global leader in family history and consumer genomics, today announced a new, preliminary finding stemming from analysis of Ancestry’s COVID-19 Research Study.

Proceeds from the Offering will help accelerate development of the SARS-CoV-2 antiviral candidate, MP0420, as well as early stage clinical and preclinical pipeline assets

Evolus, Inc. announced that its strategic partner, Daewoong Pharmaceutical Co. Ltd., will invest $40 million in a five-year, unsecured, subordinated, 3% convertible note in the Company at a conversion price of $13.00, which represents a 144% premium to the closing price on July 6, 2020.

Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 2,523,611

Endo International plc (NASDAQ: ENDP) today announced that it received U.S. Food and Drug Administration (FDA) approval of Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women.

DarioHealth Corp., a pioneer in the global digital therapeutics market, announced that the company has appointed veteran health plan executive Dennis A. Matheis to its Board of Directors, effective July 2, 2020.

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced the appointment of Narinder Singh as Executive Vice President, Technical Operations. Mr. Singh is a pr